Gradient Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Gradient Investments’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$637K	Sell	31,593 -1,145	-3%	-$30.7K	0.01%	358
2026 Q2	$828K	Buy	32,738 +3,838	+13%	+$84.4K	0.01%	339
2026 Q1	$643K	Buy	+28,900	New	+$691K	0.01%	333
2022 Q1	–	Sell	-86	Closed	-$2K	–	1163
2021 Q4	$2K	Buy	+86	New	+$1.73K	﹤0.01%	1044

Other funds holding ACAD

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.14% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Gradient Investments's ACAD Position: Q3 2026 in Review

Gradient Investments reduced its Acadia Pharmaceuticals (ACAD) stake by 3.5% in Q3 2026, selling an estimated $30.7K and leaving 31,593 shares worth $637K. The position accounts for 0.01% of the portfolio, ranked #358.

Gradient Investments first reported a position in ACAD in Q4 2021 and has held it in 4 quarters since. The position peaked at $828K in Q2 2026. 38 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

Gradient Investments held 31,593 shares of Acadia Pharmaceuticals worth $637K as of Q3 2026.
Gradient Investments sold 1,145 Acadia Pharmaceuticals shares in Q3 2026, an estimated $30.7K.
Acadia Pharmaceuticals made up 0.01% of Gradient Investments's portfolio in Q3 2026, its #358 holding.
Gradient Investments first reported a position in Acadia Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
Gradient Investments's Acadia Pharmaceuticals position peaked at $828K in Q2 2026.
38 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Gradient Investments's 13F filing for Q3 2026, filed 8 Oct 2026.